Predictive factors for work-day loss in Behçet's syndrome: A multi-center study.
Behçet's disease
ocular involvement
vascular involvement
work-day loss
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
17
01
2019
revised:
20
11
2019
accepted:
21
11
2019
pubmed:
21
12
2019
medline:
17
12
2020
entrez:
21
12
2019
Statut:
ppublish
Résumé
The aim of this multi-center study was to assess predictive factors for work-day loss as an indirect cost element in Behçet's syndrome (BS). In this cross-sectional, multi-center study, 834 BS patients (F/M: 441/393, age mean: 38.4 ± 10.9 years) were included. Data were collected by a questionnaire regarding treatment protocols, disease duration, smoking pattern, frequency of medical visits during the previous year and self-reported work-day loss during the previous year. Work-day loss was observed in 16.2% of patients (M/F: 103/32). The percentages of being a smoker (81.8%), using immunosuppressive (IS) medications (82%), and having disease duration <5 years (74%) were higher in male patients with work-day loss (P < .05). The majority of males (90.9%) had more than four clinic visits during the previous year. Moreover, the mean work-day loss (30.8 ± 57.7 days) was higher in patients with vascular involvement (56.1 ± 85.9) than those without (26.4 ± 50.6 days) (P = .046). In addition, increased frequency of ocular involvement (25.9%) was also observed in patients with work-day loss compared to others (8.6%) (P = .059). Work-day loss was associated with both vascular and ocular involvement. Close associations were observed among male gender, early period of the disease, frequent medical visits, being a smoker and treatment with IS medications in patients with work-day loss.
Identifiants
pubmed: 31858715
doi: 10.1111/1756-185X.13771
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-246Informations de copyright
© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Nakata K, Tsuji T, Vietri J, Jaffe DH. Work impairment, osteoarthritis, and health-related quality of life among employees in Japan. Health Qual Life Outcomes. 2018;16:64.
Mumcu G, Lehimci F, Fidan O, et al. The assessment of work productivity and activity impairment in Behcet's disease. Turk J Med Sci. 2017;47:535-541.
Schultz AB, Chen CY, Edington DW. The cost and impact of health conditions on presenteeism to employers: a review of the literature. Pharmacoeconomics. 2009;27:365-378.
Johns G. Presenteeism in the workplace: A review and research agenda. J Organ Behav. 2010;31:519-542.
Schultz AB, Edington DW. Employee health and presenteeism: a systematic review. J Occup Rehabil. 2007;17:547-579.
Sreih AG, Alibaz-Oner F, Easley E, et al. Health-related outcomes of importance to patients with Takayasu's arteritis. Clin Exp Rheumatol. 2018;36:51-57.
Alibaz-Oner F, Can M, Ilhan B, Polat O, Mumcu G, Direskeneli H. Presence of fibromyalgia in patients with Takayasu's arteritis. Intern Med. 2013;52:2739-2742.
Yilmaz-Oner S, Ilhan B, Can M, et al. Fatigue in systemic lupus erythematosus : Association with disease activity, quality of life and psychosocial factors. Z Rheumatol. 2016;76(10):913-919.
Mumcu G, Inanc N, Taze A, Ergun T, Direskeneli H. A new mucocutaneous activity index for Behcet's disease. Clin Exp Rheumatol. 2014;32:S80-S86.
Yilmaz N, Can M, Oner FA, et al. Impaired quality of life, disability and mental health in Takayasu's arteritis. Rheumatology (Oxford). 2013;52:1898-1904.
Khan NA, Spencer HJ, Nikiphorou E, et al. Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study. Rheumatology (Oxford). 2017;56:1395-1400.
Gron KL, Ornbjerg LM, Hetland ML, et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clin Exp Rheumatol. 2014;32:869-877.
Khan NA, Spencer HJ, Abda EA, et al. Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? Ann Rheum Dis. 2012;71:1942-1949.
Mehta P, Ambrose N, Haskard DO. Work-related disability in Behcet's syndrome: a British case series. Clin Exp Rheumatol. 2014;32:S173-S174.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
Ilhan B, Can M, Alibaz-Oner F, et al. Fatigue in patients with Behcet's syndrome: relationship with quality of life, depression, anxiety, disability and disease activity. Int J Rheum Dis. 2016;21:2139-2145.
Yazici H, Seyahi E, Hatemi G, Yazici Y. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107-119.
Direskeneli H. Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60:996-1002.
Alibaz-Oner F, Karadeniz A, Ylmaz S, et al. Behcet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine. 2015;94:e494.
Alibaz-Oner F, Mumcu G, Kubilay Z, et al. Unmet need in Behcet's disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol. 2014;33:1773-1776.
Merkel PA, Aydin SZ, Boers M, et al. Current status of outcome measure development in vasculitis. J Rheumatol. 2014;41:593-598.
Hatemi G, Ozguler Y, Direskeneli H, et al. Current status, goals, and research agenda for outcome measures development in Behcet syndrome: report from OMERACT 2014. J Rheumatol. 2015;42:2436-2441.
Hatemi G, Merkel PA, Hamuryudan V, et al. Outcome measures used in clinical trials for Behcet syndrome: a systematic review. J Rheumatol. 2014;41:599-612.
Sut N, Seyahi E, Yurdakul S, Senocak M, Yazici H. A cost analysis of Behcet's syndrome in Turkey. Rheumatology (Oxford). 2007;46:678-682.
Atas N, Varan O, Babaoglu H, et al. Work productivity in patients with Behçet disease and its association with disease activity and quality of life. Br J Occup Ther. 2019;82(6):376-382.
ISG. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078-1080.
Yavuz S, Ozilhan G, Elbir Y, Tolunay A, Eksioglu-Demiralp E, Direskeneli H. Activation of neutrophils by testosterone in Behcet's disease. Clin Exp Rheumatol. 2007;25:S46-51.
Yavuz S, Akdeniz T, Hancer V, Bicakcigil M, Can M, Yanikkaya-Demirel G. Dual effects of testosterone in Behcet's disease: implications for a role in disease pathogenesis. Genes Immun. 2016;17:335-341.
Alibaz-Oner F, Aldag B, Aldag M, et al. Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular Behcet's disease. J Vasc Surg Venous Lymphat Disord. 2016;4:301-306.
Fabiani C, Vitale A, Rigante D, et al. Predictors of sustained clinical response in patients with Behcet's disease-related uveitis treated with infliximab and adalimumab. Clin Rheumatol. 2018;37:1715-1720.
Celiker H, Kazokoglu H, Direskeneli H. Conventional immunosuppressive therapy in severe Behcet's Uveitis: the switch rate to the biological agents. BMC Ophthalmol. 2018;18:261.
Namba K, Goto H, Kaburaki T, et al. A major review: current aspects of ocular Behcet's disease in Japan. Ocul Immunol Inflamm. 2015;23(Suppl 1):S1-23.
Bulur I, Onder M. Behcet disease: new aspects. Clin Dermatol. 2017;35:421-434.
Urruticoechea-Arana A, Cobo-Ibanez T, Villaverde-Garcia V, et al. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behcet's disease associated uveitis: a systematic review. Rheumatol Int. 2018;39:47-58.
Hamuryudan V, Hatemi G, Sut N, Ugurlu S, Yurdakul S, Yazici H. Frequent oral ulceration during early disease may predict a severe disease course in males with Behcet's syndrome. Clin Exp Rheumatol. 2012;30:S32-S34.
McEvoy JW, Nasir K, DeFilippis AP, et al. Relationship of cigarette smoking with inflammation and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35:1002-1010.
Kakafika AI, Mikhailidis DP. Smoking and aortic diseases. Circ J. 2007;71:1173-1180.
Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality-beyond established causes. N Engl J Med. 2015;372:631-640.
Suwa K, Flores NM, Yoshikawa R, Goto R, Vietri J, Igarashi A. Examining the association of smoking with work productivity and associated costs in Japan. J Med Econ. 2017;20:938-944.
Wagner EH. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract. 1998;1:2-4.
Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001.